1268881-20-4 (APD 371 - Bio-X,Olorinab)

Olorinab;APD371;APD 371 - Bio-X;581F7DFA9B;APD 371;1H-Cyclopropa(4,5)cyclopenta(1,2-c)pyrazole-3-carboxamide, 4,4a,5,5a-tetrahydro-N-((1S)-1-(hydroxymethyl)-2,2-dimethylpropyl)-1-(4-oxido-2-pyrazinyl)-, (4aS,5aS)-;Olorinab [USAN];GTPL10058;BDBM50285941;compound 6 [PMID: 29259753];DB14998;BA1;(4aS,5aS)-N-[(2S)-1-Hydroxy-3,3-dimethylbutan-2-yl]-1-(4-oxidopyrazin-2-yl)-4,4a,5,5a-tetrahydro-1H-cyclopropa[4,5]cyclopenta[1,2-c]pyrazole-3-carboxamide;(2S,4S)-N-[(2S)-1-hydroxy-3,3-dimethylbutan-2-yl]-9-(4-oxidopyrazin-4-ium-2-yl)-8,9-diazatricyclo[4.3.0.02,4]nona-1(6),7-diene-7-carboxamide;CHEMBL4175981;E88367;UNII-581F7DFA9B;(1aS,5aS)-2-(4-Oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa(a)pentalene-4-carboxylic acid ((S)-1-hydroxymethyl-2,2-dimethyl-propyl)-amide;DA-76410;AKOS040741153;1268881-20-4;SCHEMBL11995430;3-[(2S,4S)-7-{[(2S)-1-hydroxy-3,3-dimethylbutan-2-yl]carbamoyl}-8,9-diazatricyclo[4.3.0.0,nona-1(6),7-dien-9-yl]pyrazin-1-ium-1-olate;BA165146;(4aS,5aS)-N-((2S)-1-hydroxy-3,3-dimethylbutan-2-yl)-1-(4-oxidopyrazin-2-yl)-4,4a,5,5a-tetrahydro-1H-cyclopropa(4,5)cyclopenta(1,2-c)pyrazole-3-carboxamide;APD-371;OLORINAB [INN];Olorinab [WHO-DD];

ACSQLTBPYZSGBA-GMXVVIOVSA-N

1S/C18H23N5O3/c1-18(2,3)13(9-24)20-17(25)15-12-7-10-6-11(10)16(12)23(21-15)14-8-22(26)5-4-19-14/h4-5,8,10-11,13,24H,6-7,9H2,1-3H3,(H,20,25)/t10-,11-,13+/m0/s1

O=C(C1C2=C([C@H]3C[C@H]3C2)N(C2C=[N+](C=CN=2)[O-])N=1)N[C@H](CO)C(C)(C)C